Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H1WC
|
|||
| Former ID |
DIB007400
|
|||
| Drug Name |
LY3023414
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [2] | ||
| Company |
Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H26N4O3
|
|||
| Canonical SMILES |
CC(CN1C2=C3C=C(C=CC3=NC=C2N(C1=O)C)C4=CC(=CN=C4)C(C)(C)O)OC
|
|||
| InChI |
1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1
|
|||
| InChIKey |
ACCFLVVUVBJNGT-AWEZNQCLSA-N
|
|||
| CAS Number |
CAS 1386874-06-1
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02549989) Study of LY3023414 for the Treatment of Recurrent. | |||
| REF 3 | Company report (Lilly) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.